13APR

Cytospire's £61m oncology Series A oversubscribed

3 min read

17:59UTC

Cytospire Therapeutics, a London biotech incorporated in February 2023, closed an oversubscribed £61m Series A on 5 May with the British Business Bank contributing £12m alongside international specialist funds.

← Back to State capital floods in, seed money drains Jump to analysis ↓

TechnologyDeveloping

Key takeaway

Cytospire's oversubscribed £61m Series A at under three years old shows UK oncology attracts specialist international capital pre-clinical.

Cytospire Therapeutics, a London biotech incorporated in February 2023, closed an oversubscribed £61m Series A on 5 May 2026. 4BIO Capital led the round; Servier Ventures, Abingworth, LifeArc Ventures, Sound Bioventures, and Medical Incubator Japan participated. The British Business Bank (BBB) contributed £12m, drawing on the direct-investment mandate that activated in April 2026, the same instrument behind the £40m Quantum Motion cornerstone . ¹

Cytospire's lead programme, CYT X300, is a first-in-class pan-gamma delta T cell engager targeting EGFR (Epidermal Growth Factor Receptor)-positive solid tumours. Existing cancer immunotherapy approaches typically target specific gamma delta T cell subtypes; CYT X300 targets all subtypes simultaneously, which is the mechanism the company claims distinguishes it clinically. Funds from the Series A go toward IND-enabling (Investigational New Drug) studies and Good Manufacturing Practice (GMP) manufacturing ahead of a first-in-human trial.

CellCentric closed its Series D on the same day, drawing exclusively private institutional capital from US and European healthcare funds, plus Pfizer as a strategic participant; Cytospire drew the BBB as a public co-investor alongside international specialist biotech funds. Two UK oncology rounds, one calendar day, two entirely different capital structures. The DSIT Life Sciences Innovative Manufacturing Fund had already allocated over £80m to four regional manufacturing sites on 14 April , signalling that DSIT-adjacent capital is entering life sciences at multiple points along the development chain. The BBB's presence in a sub-£100m Series A where private capital was already oversubscribing raises the additionality question the mandate was supposed to address: the fund is entering rounds where demand already exceeds supply, not rounds where private capital has declined to participate.

For UK oncology founders, the data point is the oversubscription at less than three years from incorporation: a first-in-class mechanism, no clinical data yet, and specialist international co-investors willing to lead. The BBB's £12m did not anchor the round; 4BIO Capital led it.

Deep Analysis

In plain English

Cytospire has developed a cancer treatment that works by recruiting a type of immune cell called gamma delta T cells to attack tumours. Existing cancer immunotherapies target specific subtypes of these cells; Cytospire's drug, CYT X300, is designed to engage all of them at once, potentially treating a wider range of patients with EGFR-positive solid tumours, a category that includes some lung, colorectal, and head and neck cancers. The company raised £61m in May 2026, just over three years after it was founded in London. The British Business Bank put in £12m alongside specialist cancer investment funds from the UK, France, Japan, and the US. The money funds safety testing studies and manufacturing preparation before the first clinical trial in humans.

Deep Analysis

Root Causes

The BBB's £12m contribution to an oversubscribed Series A illustrates the additionality question embedded in the new mandate.

Private capital led by 4BIO Capital and backed by Servier Ventures, Abingworth, and LifeArc Ventures had already pushed the round past its target. The BBB entered a round where private institutional appetite exceeded supply, which is the opposite of the seed-gap market failure the mandate was designed to address.

What could happen next?

Opportunity
Cytospire's international syndicate including Medical Incubator Japan positions the company for early Asian licensing discussions, a capital-efficient route to funding Phase 1 without requiring a US listing.

Source Landscape

This story draws on neutral-leaning sources

Primary parallel: The 2016 to 2019 wave of UK CAR-T (chimeric antigen receptor T cell) companies, including Autolus Therapeutics (UCL spinout, listed on Nasdaq 2018), showed that British academic immunotherapy programmes can attract international Series A capital before clinical proof of concept when the mechanism is genuinely first-in-class.

Autolus raised £120m in its 2018 IPO on the strength of preclinical and Phase 1 data. Cytospire is following the same pattern at the same stage with a different T cell modality.

Counter-parallel: Kymera Therapeutics, a Boston immunotherapy company, raised $102m in a 2021 Series C on targeted protein degradation; its lead programme entered Phase 2 in 2023 but produced a clinical hold in 2024. First-in-class mechanism does not guarantee clinical success, and Cytospire's IND-enabling stage means investors are pricing in a multi-year clinical risk period with no human safety data yet.

At £61m Series A for a company incorporated in February 2023, Cytospire's implied post-money valuation positions it at the upper end of preclinical UK biotech, consistent with first-in-class mechanism pricing by specialist institutional funds.

The Japanese co-investor Medical Incubator Japan signals that Asian pharma groups are monitoring UK oncology immunotherapy for licensing optionality, which compresses the timeline to a potential non-dilutive licensing deal alongside the clinical programme.

Consensus view: 4BIO Capital's managing partners assess pan-gamma delta T cell engagers as a clinically distinct approach to solid tumour immunotherapy: unlike checkpoint inhibitors (pembrolizumab, nivolumab) which release existing T cell activity, CYT X300 recruits gamma delta T cells as effectors across the full heterogeneous population of EGFR-positive tumour subtypes.

The oversubscription at less than three years from incorporation reflects specialist investors pricing clinical optionality before Phase 1 data.

Counter-view: The Francis Crick Institute's immunology group notes that pan-gamma delta engagement has produced cytokine release syndrome in preclinical models. First-in-human trial design will require careful dose-escalation protocols, and the IND-enabling stage that Cytospire is funding carries significant safety risk before efficacy data exist.

Key tension: Whether pan-gamma delta T cell engagement can maintain tumour selectivity across heterogeneous patient populations without triggering systemic immune responses that limit the therapeutic window.

First Reported In

Update #4 · State capital lands on UK tech in nine days

BioSpace (via GlobeNewswire)· 13 May 2026

Read original →

Causes and effects

Caused by

Business Bank begins direct startup investment

The BBB's £12m Cytospire co-investment is direct-mandate capital under the £6.6bn expansion activated in April 2026 (ID:2343).

Occurred 6 Apr 2026

Read story →

This Event

Cytospire's £61m oncology Series A oversubscribed

Cytospire's oversubscribed round at less than three years old shows that UK oncology immunotherapy companies with first-in-class mechanisms can attract large Series A rounds from international specialist capital, with public co-investment from the BBB entering rounds where private institutional appetite is already present.

Led to

State £50m backs the tier funds skip

The BBB's £12m into Cytospire (ID:3277) is part of the same £6.6bn direct mandate deployment that backstops Longwall Fund 4.

Occurred 27 May 2026

Read story →

Different Perspectives

European limited partners (Plural, Aviva Investors)

Pan-European fund Plural led Orbital's $50m and Aviva Investors co-anchored the BBB's Lansdowne spinout fund (event ID:3505), demonstrating that Continental and UK institutional capital can fill the growth-stage tier independently, though neither has the scale to compete with US growth funds at the $100m+ band that successive ex-DeepMind rounds will eventually reach.

France (DSIT / GENCI / Institut Pasteur)

France signed the UK-France Strategic Biomedical Alliance on 29 May, contributing €330,000 a year to researcher mobility and linking GENCI national compute to Isambard-AI; the bilateral format suits Paris because it produces scientific access without requiring EU-framework ratification while the UK-EU science relationship remains unsettled.

US growth investors (NVentures, General Catalyst, Crosspoint Capital)

NVentures entering Orbital's cap table for the first time and General Catalyst following on in Geordie's Series A signals US growth investors treating London deeptech as a buy-side opportunity the UK market cannot contest. NVentures gains supply-chain visibility into GPU cooling; General Catalyst gains a frontier security category the RSAC prize has already validated for US enterprise.

UK Government (DSIT / British Business Bank)

The BBB cornerstoned Longwall at the seed floor on 27 May while DSIT signed the UK-France bilateral compute deal the same week, deploying state capital at bottom and research layers simultaneously. Neither instrument addresses the Series B middle the April 2026 mandate expansion could reach but has not.

Australian Department of Defence (AUKUS partner, Rowden Technologies)

Rowden Technologies holds active AUKUS AI for Acoustics contracts with the UK, US and Australian defence establishments. The NWF's £25m investment in Rowden on 13 May places UK sovereign capital directly into a trilateral programme Australia co-funds; from Canberra's perspective, the NWF cheque increases UK government skin-in-the-game on a programme where Australia has already committed co-development resources.

Temasek (Singapore sovereign co-investor, Isomorphic Series B)

Temasek co-invested with the SAIU in Isomorphic's $2.1bn Series B the previous week, treating a majority Alphabet-owned company as a valid sovereign co-investment target. Fractile's round, without a UK sovereign co-investor, reads differently from Singapore's vantage: allied state capital (NATO-IF, In-Q-Tel) is now competing with Asian sovereign funds for early positions in UK deeptech.